Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine

Vaccine

Volumn 29, Issue 2, 2010, Pages 174-182

  Nelson, Michelle H ^a   Winkelmann, Evandro ^a   Ma, Yinghong ^a   Xia, Jingya ^a   Mason, Peter W ^a,b   Bourne, Nigel ^a   Milligan, Gregg N ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Microbial Molecular Biology   (United States)

Author keywords

CD8+ T cell; IgG subclass; Single cycle virus; West Nile virus

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN G2C ANTIBODY; INTERLEUKIN 4; REPLIVAX WN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN; WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS DETECTION; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY TESTS, IMMUNOLOGIC; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 78649697513     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.069     Document Type: Article

References (36)

1. Gea-Banacloche J., Johnson R.T., Bagic A., Butman J.A., Murray P.R., Agrawal A.G. West Nile virus: pathogenesis and therapeutic options. Annals of Internal Medicine 2004, 140(April (7)):545-553.
2. Granwehr B.P., Lillibridge K.M., Higgs S., Mason P.W., Aronson J.F., Campbell G.A., et al. West Nile virus: where are we now?. The Lancet Infectious Diseases 2004, 4(September (9)):547-556.
3. Diamond M.S., Shrestha B., Marri A., Mahan D., Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. Journal of Virology 2003, 77(February (4)):2578-2586.
4. Engle M.J., Diamond M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. Journal of Virology 2003, 77(December (24)):12941-12949.
5. Diamond M.S., Sitati E.M., Friend L.D., Higgs S., Shrestha B., Engle M. A critical role for induced IgM in the protection against West Nile virus infection. The Journal of Experimental Medicine 2003, 198(December (12)):1853-1862.
6. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005, 437(September (7059)):764-769.
7. Kaufmann B., Nybakken G.E., Chipman P.R., Zhang W., Diamond M.S., Fremont D.H., et al. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(August (33)):12400-12404.
8. Diamond M.S., Pierson T.C., Fremont D.H. The structural immunology of antibody protection against West Nile virus. Immunological Reviews 2008, 225:212-225. October.
9. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nature Medicine 2005, 11(May (5)):522-530.
10. Mehlhop E., Whitby K., Oliphant T., Marri A., Engle M., Diamond M.S. Complement activation is required for induction of a protective antibody response against West Nile virus infection. Journal of Virology 2005, 79(June (12)):7466-7477.
11. Mukhopadhyay S., Kuhn R.J., Rossmann M.G. A structural perspective of the flavivirus life cycle. Nature Reviews 2005, 3(January (1)):13-22.
12. Chung K.M., Nybakken G.E., Thompson B.S., Engle M.J., Marri A., Fremont D.H., et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. Journal of Virology 2006, 80(February (3)):1340-1351.
13. Wang Y., Lobigs M., Lee E., Mullbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. Journal of Virology 2003, 77(December (24)):13323-13334.
14. Shrestha B., Diamond M.S. Role of CD8+ T cells in control of West Nile virus infection. Journal of Virology 2004, 78(August (15)):8312-8321.
15. Brien J.D., Uhrlaub J.L., Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. European Journal of Immunology 2007, 37(July (7)):1855-1863.
16. Purtha W.E., Myers N., Mitaksov V., Sitati E., Connolly J., Fremont D.H., et al. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. European Journal of Immunology 2007, 37(July (7)):1845-1854.
17. Sitati E.M., Diamond M.S. CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. Journal of Virology 2006, 80(December (24)):12060-12069.
18. Brien J.D., Uhrlaub J.L., Nikolich-Zugich J. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. Journal of Immunology 2008, 181(December (12)):8568-8575.
19. Mason P.W., Shustov A.V., Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication. Virology 2006, 351(August (2)):432-443.
20. Widman D.G., Frolov I., Mason P.W. Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses. Advances in Virus Research 2008, 72:77-126.
21. Widman D.G., Ishikawa T., Fayzulin R., Bourne N., Mason P.W. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008, 26(May (22)):2762-2771.
22. Widman D.G., Ishikawa T., Winkelmann E.R., Infante E., Bourne N., Mason P.W. RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 2009, 27(September (41)):5550-5553.
23. Fayzulin R., Scholle F., Petrakova O., Frolov I., Mason P.W. Evaluation of replicative capacity and genetic stability of West Nile virus replicons using highly efficient packaging cell lines. Virology 2006, 351(July (1)):196-209.
24. Johnson A.J., Nelson M.H., Bird M.D., Chu C.F., Milligan G.N. Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection. Journal of Reproductive Immunology 2010, 84(1):8-15.
25. Widman D.G., Ishikawa T., Giavedoni L.D., Hodara V.L., Garza Mde L., Montalbo J.A., et al. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. American Journal of Tropical Medicine and Hygiene 2010, 82(6):1160-1167.
26. Slifka M.K., Matloubian M., Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. Journal of Virology 1995, 69(March (3)):1895-1902.
27. Macdonald J., Tonry J., Hall R.A., Williams B., Palacios G., Ashok M.S., et al. NS1 protein secretion during the acute phase of West Nile virus infection. Journal of Virology 2005, 79(November (22)):13924-13933.
28. Mason P.W. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells. Virology 1989, 169(April (2)):354-364.
29. Libraty D.H., Young P.R., Pickering D., Endy T.P., Kalayanarooj S., Green S., et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. The Journal of Infectious Diseases 2002, 186(October (8)):1165-1168.
30. Alcon S., Talarmin A., Debruyne M., Falconar A., Deubel V., Flamand M. Enzyme-linked immunosorbent assay specific to dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. Journal of Clinical Microbiology 2002, 40(February (2)):376-381.
31. Mutoh E., Ishikawa T., Takamizawa A., Kurata T., Sata T., Kojima A. Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone. Vaccine 2004, 22(June (20)):2599-2608.
32. Konishi E., Pincus S., Paoletti E., Shope R.E., Burrage T., Mason P.W. Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology 1992, 188(June (2)):714-720.
33. Hanna S.L., Pierson T.C., Sanchez M.D., Ahmed A.A., Murtadha M.M., Doms R.W. N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. Journal of Virology 2005, 79(November (21)):13262-13274.
34. Schlick P., Kofler R.M., Schittl B., Taucher C., Nagy E., Meinke A., et al. Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations. Vaccine 2010, 28(36):5903-5909.
35. Pletnev A.G., Swayne D.E., Speicher J., Rumyantsev A.A., Murphy B.R. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 2006, 24(September (40-41)):6392-6404.
36. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(April (17)):6694-6699.